Emerging research links GLP-1 drugs to potential reduction in breast cancer recurrence

New studies suggest that GLP-1 receptor agonists like Ozempic and Wegovy may be associated with lower breast cancer recurrence rates, though experts emphasise that further research is needed before changing clinical practices.

Medicines such as Ozempic and Wegovy, which belong to the GLP-1 class and are already used for diabetes and weight management, are drawing interest for reasons that go beyond blood sugar control and slimming. According to reporting from România Liberă, fresh research presented at the 2026 annual meeting of the American Society of Clinical Oncology has raised the possibility that these drugs may also be linked to a lower risk of some cancers returning, particularly breast cancer, although specialists stress that the evidence remains associative rather than causal. The American Cancer Society has likewise said emerging findings suggest a possible cancer-risk reduction signal, but it emphasises that GLP-1 drugs are not approved for cancer prevention.

Texas breast cancer surgeon Dr Loren Rourke told România Liberă that the latest ASCO findings point to a relationship between GLP-1 use and lower recurrence rates in breast cancer, but he underlined that the studies so far are observational. In other words, they can show correlation, not prove that the medicines themselves are preventing cancer. A study abstract published by ASCO this year also examined cancer incidence and mortality in patients with chronic kidney disease taking GLP-1 receptor agonists, reflecting wider scientific interest in whether the drugs may influence cancer outcomes beyond weight loss alone.

One explanation is biological rather than purely statistical. Rourke said the effect may be driven in part by weight loss, since a lower body-mass index is associated with better outcomes in breast cancer, and by the fall in adipose tissue, which can reduce oestrogen production. That matters because higher oestrogen levels can encourage the growth of some breast cancers. He also pointed to reduced chronic inflammation, which can create a more favourable environment for cancer cells. Similar themes have emerged in other research, including a retrospective cohort study suggesting lower rates of liver and pancreatic cancers among patients with type 2 diabetes who started GLP-1 receptor agonists, and a Healthline report on University of Pennsylvania research that found roughly a 30% lower breast cancer risk among women using GLP-1 drugs.

For now, doctors say the findings are intriguing but not practice-changing. Researchers still need randomised clinical trials, the gold standard for medical evidence, before anyone can say whether GLP-1 medicines directly reduce cancer risk or whether the benefit is mainly a by-product of better overall health and weight loss. Rourke said people with obesity who have not been able to lose weight through diet and exercise may wish to discuss these treatments with their doctors if they are eligible, while women going through the menopause and struggling with weight gain may also have questions worth raising in clinic. Even so, the current consensus is that GLP-1 drugs should continue to be used for the conditions for which they have been approved, with any cancer-prevention role still firmly under investigation.